2.2 Transcutaneous Electrical Nerve Stimulation (TENS) Modes & Protocols

Transcutaneous Electrical Nerve Stimulation (TENS) Modes & Protocols

Transcutaneous Electrical Nerve Stimulation (TENS) is an evidence-based electrotherapeutic modality designed specifically for the non-invasive, non-pharmacological management of acute, subacute, and chronic pain. In chiropractic clinical practice, TENS serves as a critical adjunctive tool to downregulate central and peripheral nociception, break the reflexive pain-spasm-pain cycle, and create a therapeutic window for active rehabilitation and spinal manipulative therapy.

The Neurobiological Mechanisms of TENS

TENS modulates pain perception primarily through two distinct neurophysiological mechanisms:

1. The Spinal Gate Control Theory (Melzack & Wall, 1965): Non-noxious sensory input conveyed along large-diameter, myelinated $\text{A}\beta$ (A-beta) afferent fibers enters the dorsal horn of the spinal cord. These fibers send collateral branches into the substantia gelatinosa (Laminae II and III), exciting inhibitory GABAergic and enkephalinergic interneurons. These interneurons presynaptically inhibit the central transmission cells (T-cells) in Lamina V, closing the "gate" against incoming noxious impulses carried by small-diameter $\text{A}\delta$ (A-delta) and C fibers traveling up the spinothalamic tract.
2. The Endogenous Opioid Hypothesis: Low-frequency, rhythmic motor-level stimulation activates muscle ergoreceptors (Group III and IV afferents), transmitting signals via the spinothalamic tract to the periaqueductal gray (PAG) matter of the midbrain and the nucleus raphe magnus (NRM) of the rostral ventromedial medulla. This triggers the synthesis and systemic release of $\beta$-endorphin from the pituitary gland and hypothalamus, along with dynorphins and enkephalins in the cerebrospinal fluid. These endogenous peptides bind to $\mu$- and $\delta$-opioid receptors, depressing pain transmission at both presynaptic and postsynaptic sites. This analgesic mechanism can be experimentally blocked by the opioid antagonist naloxone.

Clinical Comparison of the Four TENS Modes

Clinical success with TENS requires prescribing specific parameter sets tailored to the patient's pathology, chronicity, and tolerance.

1. Conventional TENS (High-Frequency / Sensory-Level)

• Frequency: High, $50–150\text{ Hz}$ (typically set at $80–100\text{ pps}$).
• Pulse Duration: Narrow, $50–100\ \mu s$.
• Amplitude / Intensity: Sensory-level. The patient experiences a comfortable, strong, non-painful tingling, fluttering, or buzzing sensation beneath and between the pads. No muscle twitches or contractions should be visible or palpable.
• Mechanism: Exclusively Gate Control Theory (selective $\text{A}\beta$ depolarization).
• Onset of Analgesia: Rapid (typically within $5–15\text{ minutes}$). However, the analgesic carryover post-treatment is short (typically $30\text{ minutes to }2\text{ hours}$ after shutting off the unit).
• Treatment Duration: $30–60\text{ minutes}$, or worn continuously during daily functional activities.
• Indications: Acute musculoskeletal injuries (e.g., acute cervical whiplash, acute lumbar sprain/strain), post-surgical incision pain, acute radiculopathy flare-ups, and early-phase joint inflammation.

2. Low-Frequency TENS (Acupuncture-Like / Motor-Level)

• Frequency: Low, $1–10\text{ Hz}$ (optimally $2–4\text{ pps}$).
• Pulse Duration: Wide, $150–300\ \mu s$.
• Amplitude / Intensity: Motor-level. Adjusted until visible, rhythmic, forceful muscle fasciculations or twitches occur at the set frequency (e.g., 2–4 rhythmic contractions per second). The contractions must remain tolerable without inducing cramp or sharp pain.
• Mechanism: Endogenous Opioid Release (systemic $\beta$-endorphin and dynorphin release; completely reversed by naloxone administration).
• Onset of Analgesia: Delayed (requires $20–30\text{ minutes}$ of stimulation to achieve therapeutic circulating opioid concentrations).
• Carryover Effect: Substantial and prolonged ($4–6+\text{ hours}$ of post-treatment pain reduction).
• Treatment Duration: Strictly limited to $20–30\text{ minutes}$. Prolonged continuous motor stimulation causes local muscular fatigue, micro-trauma, and delayed-onset muscle soreness (DOMS).
• Indications: Chronic pain syndromes (chronic myofascial pain syndrome, chronic lumbosacral spondylosis, osteoarthritis, post-stroke shoulder subluxation pain).

3. Brief Intense TENS (Noxious-Level)

• Frequency: High, $100–150\text{ Hz}$.
• Pulse Duration: Wide, $150–250\ \mu s$.
• Amplitude / Intensity: Noxious / maximal tolerable. Current is driven to the patient's highest tolerable tolerance, eliciting intense non-painful or painful paresthesia combined with tetanic muscle contraction.
• Mechanism: Descending Noxious Inhibitory Control (DNIC) and temporary peripheral axon conduction block. The overwhelming sensory barrage temporarily depletes presynaptic neurotransmitter pools and triggers descending serotonergic and noradrenergic inhibitory tracts from the brainstem.
• Onset of Analgesia: Immediate, producing profound local anesthesia/numbness.
• Carryover Effect: Short to moderate ($30–60\text{ minutes}$).
• Treatment Duration: Brief, $10–15\text{ minutes}$ maximum.
• Indications: Applied immediately prior to painful therapeutic interventions, such as deep friction cross-fiber massage, aggressive manual joint mobilization, passive contracture stretching, or trigger point dry needling.

4. Burst Mode TENS (Pulse-Train / Combination)

• Waveform Structure: High-frequency carrier pulses (typically $70–100\text{ Hz}$) grouped into discreet "packets" or bursts delivered at a low repetition rate of $1–5\text{ bursts per second}$.
• Pulse Duration: Moderate, $100–200\ \mu s$.
• Amplitude / Intensity: Set to produce visible rhythmic muscle contractions at the burst frequency (e.g., 2 to 3 rhythmic muscle beats per second).
• Mechanism: Combines both the Gate Control Theory and Endogenous Opiate Release pathways.
• Clinical Rationale: Single pulses delivered at low frequencies (2 Hz) in Acupuncture-like TENS can feel sharp, pricking, or stinging to sensitive patients. Grouping pulses into bursts delivers high electrical charge more comfortably, enhancing patient compliance while still eliciting forceful motor contractions and endorphin synthesis.

Comparison of TENS Modes

Prevention of Nerve Accommodation: Modulation Parameters

A persistent clinical challenge during prolonged TENS application is accommodation—the physiological process whereby nerve cell membranes adapt to constant, repetitive electrical stimuli by raising their depolarization threshold. Patients report that the stimulation "faded away" after 10–15 minutes, leading to reduced analgesia.

Modern digital TENS units combat accommodation by incorporating automated Modulation Modes that dynamically cycle parameter settings in regular or random sequences:

• Frequency Modulation (FM): The unit automatically sweeps the pulse rate across a preset range (e.g., cycling from $50\text{ Hz}$ to $100\text{ Hz}$ and back over a 5-second cycle). This prevents accommodation of the spinal interneurons.
• Pulse Width Modulation (PWM): The unit continually widens and narrows the pulse duration by $\pm 25–50%$.
• Amplitude Modulation (AM): The peak current automatically ramps up and down in intensity.
• Multi-Modulation (Comb): Simultaneously varies frequency, width, and amplitude. Recommended whenever TENS is applied for extended sessions ($>45\text{ minutes}$).

Clinical Electrode Placement Strategies

Electrode positioning directly governs which neural pathways are recruited. Clinicians utilize four primary placement configurations:

1. Dermatomal / Spinal Segmental Placement: Electrodes are positioned along the paraspinal nerve root emergence corresponding to the spinal segment supplying the painful extremity (e.g., L4–S1 paraspinals for posterolateral sciatica, or C5–C7 paraspinals for cervical radiculopathy). This addresses referred and radicular pain at the spinal level.
2. Peripheral Nerve Pathway: Electrodes are placed directly along the anatomical course of the peripheral nerve proximal to the lesion site (e.g., along the superficial trunk of the common peroneal or ulnar nerve).
3. Bracketed / Criss-Cross Placement (Dual Channel): Four electrodes (two channels) surround the focal area of pain. Channel 1 and Channel 2 are aligned diagonally such that the lines between pad pairs cross over the central point of pain (e.g., enclosing an arthritic knee, glenohumeral joint, or lumbar facet arthropathy).
4. Myofascial Trigger Points and Acupuncture Points: Electrodes are positioned directly over localized hyperirritable nodules in taut muscle bands. These sites exhibit reduced electrical skin resistance, optimizing current penetration into somatic sensory pathways.

Absolute Contraindications and Clinical Safety Guidelines

Prior to applying TENS, the chiropractic clinician must perform pre-treatment sensory testing (light touch / sharp-dull) and rule out absolute contraindications:

• Cardiac Pacemakers & AICDs: Electrical signals can interfere with demand-type cardiac pacemakers or implantable cardioverter-defibrillators, inducing pacing inhibition or triggering inappropriate defibrillation shocks. (Absolute contraindication anywhere on the torso or upper extremities).
• Carotid Sinus Region: Placing electrodes over the anterior/lateral neck (carotid bifurcation) can stimulate baroreceptors, triggering sudden profound bradycardia, acute hypotension, and syncope.
• Active Thrombophlebitis / DVT: Stimulation over veins with suspected or confirmed thrombosis can mechanically dislodge a clot, leading to pulmonary embolism.
• Anterior Neck / Phrenic Nerve / Laryngeal Muscles: Risk of inducing vocal cord adduction, laryngeal spasm, and respiratory arrest.
• Gravid Uterus During Pregnancy: Placement over the abdomen, pelvis, lower back, or sacrum during pregnancy is strictly contraindicated due to the risk of inducing premature uterine contractions. (TENS may be used on the lower extremities for distal neuropathies, or during active labor by trained obstetrical personnel).
• Transcerebral / Transthoracic Lead Placement: Never place electrodes across the cranium (seizure risk) or transthoracically (across the heart vector, ventricular fibrillation risk).
• Active Local Malignancy: Electrotherapy enhances microvascular perfusion and cellular metabolic activity, potentially promoting neoplastic metastasis.
• Uncontrolled Epilepsy: Transcerebral or upper spinal leads can provoke seizure activity.
• Impaired Sensation / Denervated Skin: Severe diabetic neuropathy or sensory loss impairs patient feedback, increasing burn risk.